About this Journal Submit a Manuscript Table of Contents
ISRN Dermatology
Volume 2014 (2014), Article ID 932721, 8 pages
http://dx.doi.org/10.1155/2014/932721
Clinical Study

Clinical and Contrast-Enhanced Ultrasound Echography Outcomes in Psoriatic Arthritis Patients after One Year of Continuous Therapy with Anti-TNF Drugs

1Centre for the Study and Treatment of Psoriasis, Department of Clinical Dermatology, San Gallicano Dermatologic Institute (IRCCS), Via Elio Chianesi 53, 00144 Rome, Italy
2Radiodiagnostic Service, San Gallicano Dermatologic Institute (IRCCS), 00144 Rome, Italy
3Department of Rheumatology, San Camillo-Forlanini Hospital, 00151 Rome, Italy

Received 17 November 2013; Accepted 22 December 2013; Published 6 February 2014

Academic Editors: G. Chodorowska, P. Fernandez-Penas, and F. Kaneko

Copyright © 2014 Claudio Bonifati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. We wanted to verify retrospectively the proportion of patients with psoriatic arthritis who were in remission after 1 year of continuous therapy with either etanercept or adalimumab. Remission was defined as the absence of both clinical and contrast-enhanced ultrasound (CEUS) findings suggestive of joint inflammation. Patients and Methods. The data of twenty-five patients with psoriatic arthritis were available for the clinical and CEUS evaluations before and after 1 year of continuous therapy with etanercept or adalimumab. The count of swollen (ACR66), tender (ACR68), and active inflamed joints (AJC) was used to measure the severity of joint involvement. PASI was used to score the severity of psoriasis. HAQ, DLQI, VAS pain, and VAS itching were administered to each patient before starting therapy and every 3 months, up to 1 year. Results. Eight (32%) out of twenty-five patients were in remission after 1 year of therapy with etanercept or adalimumab. A significant reduction of all clinical variables analysed was seen during the course of therapy. Conclusion. Although a significant proportion of patients achieved remission of arthritis after 1 year of effective anti-TNF therapy, the majority of them continued to have either clinical or CEUS findings suggestive of persistence of joint inflammation.